U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07326852) titled 'Hybrid Assistive Limb Application in Multiple Sclerosis Patients' on Nov. 18, 2025.
Brief Summary: The Hybrid Assistive Limb (HAL) exoskeleton detects bioelectrical signals from the muscles, responds to the intention of voluntary movement, and provides biological feedback. In this study, the effects of HAL application on walking performance and balance in patients with multiple sclerosis will be examined in a single-center, controlled design. Participants will undergo walking rehabilitation with HAL for 1 hour per day, 5 days a week, for a total of 2 months. Walking and balance performance will be assessed before and after the interv...